Table 4.
Solicited vaccination reactions after a booster dose of BNT162b2 after the initial receipt of a complete CoronaVac regimen
| Age <60 years (n=28) | Age ≥60 years (n=42) | All (N=70*) | ||
|---|---|---|---|---|
| Any reaction | 25 (89·3%) | 31 (73·8%) | 56 (80·0%) | |
| Local reaction | 24 (85·7%) | 27 (64·3%) | 51 (72·9%) | |
| Pain | 24 (85·7%) | 25 (59·5%) | 49 (70·0%) | |
| Induration | 6 (21·4%) | 9 (21·4%) | 15 (21·4%) | |
| Redness | 0 | 3 (7·1%) | 3 (4·3%) | |
| Systemic reaction | 17 (60·7%) | 12 (28·6%) | 29 (41·4%) | |
| Malaise | 12 (42·9%) | 7 (16·7%) | 19 (27·1%) | |
| Headache | 12 (42·9%) | 7 (16·7%) | 19 (27·1%) | |
| Myalgia | 9 (32·1%) | 0 | 9 (12·9%) | |
| Joint pain | 10 (35·7%) | 0 | 10 (14·3%) | |
| Fever and shivering | 7 (25·0%) | 0 | 7 (10·0%) | |
| Shivering | 3 (10·7%) | 0 | 3 (4·3%) | |
| Fever | 6 (21·4%) | 0 | 6 (8·6%) | |
| Nausea | 3 (10·7%) | 0 | 3 (4·3%) | |
| Vomiting | 1 (3·6%) | 0 | 1 (1·4%) | |
| Dizziness | 4 (14·3%) | 0 | 4 (5·7%) | |
| Diarrhoea | 0 | 0 | 0 | |
| Stomach-ache | 2 (7·1%) | 0 | 2 (2·9%) | |
Data presented as n (%).
*
Of the 85 participants evaluated in this group, 70 responded to the survey after the booster dose.